Evidence map›Paper›PMID 33011088›Full record

SynthesisDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver2021

Metabolic associated fatty liver disease increases the severity of COVID-19: A meta-analysis.

Lu Pan, Pan Huang, Xia Xie, Jiachen Xu, Dawei Guo, Yuan Jiang

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 6 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 6 syntheses or guidelines pooled it, 91 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Lu PanDepartment of Critical Care Unit, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, No. 3002, Sungang west Road, Futian District, Shenzhen, China.
Pan HuangCollege of Nursing, Gannan Medical University, No. 1 Hexie Road, Rongjiang New area, Ganzhou, China. Electronic address: gnyxywthp@163.com.
Xia XieCollege of Nursing, North Sichuan Medical College, No. 234, Fujiang Road, Shunqing District, Nanchong City, Sichuan, China. Electronic address: 583564979@qq.com.
Jiachen XuDepartment of medicine, JingGangshan University,Ji'an,Jiangxi province,China, No.28 Xueyuan Road, Qingyuan District, Ji 'an City, China.
Dawei GuoDepartment of medicine, JingGangshan University,Ji'an,Jiangxi province,China, No.28 Xueyuan Road, Qingyuan District, Ji 'an City, China.
Yuan JiangDepartment of medicine, JingGangshan University, Ji'an,Jiangxi province,China, No.28 Xueyuan Road, Qingyuan District, Ji 'an City, China.
Jinggangshan University · CNGannan Medical University · CNNorth Sichuan Medical University · CNShenzhen Second People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe association between metabolic-associated fatty liver disease (MAFLD) and disease progression in patients with the coronavirus disease 2019 (COVID-19) are unclear.

aimsTo explore the association between MAFLD and the severity of COVID-19 by meta-analysis.

methodsWe conducted a literature search using PubMed, EMBASE, Medline (OVID), and MedRxiv from inception to July 6, 2020. Newcastle-Ottawa Scale (NOS) and Stata 14.0 were used for quality assessment of included studies as well as for performing a pooled analysis.

resultsA total of 6 studies with 1,293 participants were included after screening. Four studies reported the prevalence of MAFLD patients with COVID-19, with a pooled prevalence of 0.31 for MAFLD (95CI 0.28, 0.35, I

conclusionIn this meta-analysis, we found that a high percentage of patients with COVID-19 had MAFLD. Meanwhile, MAFLD increased the risk of disease progression among patients with COVID-19. Thus, better intensive care and monitoring are needed for MAFLD patients infected by SARS-COV-2.

Indexed as

COVID-19Fatty LiverDisease ProgressionHumansPatient Care ManagementRisk FactorsSARS-CoV-2Severity of Illness IndexCOVID-19Metabolic associated fatty liver diseaseSARS-CoV-2

Identifiers

PMID33011088
PMCPMC7498251
OpenAlexW3086502779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.